Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration
Abstract
The distinctive milieu of the bone marrow (BM), known as the BM niche, supports hematopoietic stem cells (HSCs) and serves as a foundation for hematopoietic regeneration. Myeloablative stress disrupts not only hematopoietic stem and progenitor cells but also essential BM niche components, including endothelial cells (ECs) and mesenchymal stromal cells (MSCs); disruption of the latter impairs efficient hematopoietic recovery. However, therapeutic strategies targeting niche restoration remain largely underdeveloped. Here, we demonstrate that the Hippo pathway effectors YAP/TAZ are critical for enabling ECs and MSCs to respond to BM injury, and that YAP/TAZ activation accelerates BM niche recovery, thereby promoting hematopoietic regeneration. We found that YAP/TAZ are rapidly activated in both MSCs and ECs following myeloablative stress, maintaining MSC multipotency and orchestrating vascular remodeling. Mechanistically, YAP/TAZ function as transcriptional hubs in MSCs, regulating key transcriptional factors such as Ebf1 and Ebf3. This regulation preserves MSC identity by preventing osteogenic and fibrogenic differentiation while promoting the expression of hematopoietic factors such as Cxcl12 and angiogenic factors. In addition, YAP/TAZ signaling in MSCs and ECs appeared to coordinately remodel sinusoidal vessels following BM injury. These YAP/TAZ-mediated niche responses are essential for HSC retention and hematopoietic regeneration following diverse myelosuppressive therapies. Notably, pharmacological activation of YAP/TAZ enhances BM niche reorganization and augments hematopoietic regeneration following myeloablative therapies. These findings establish YAP/TAZ as central regulators of BM niche resilience, providing a rationale for niche-targeted therapeutic strategies to enhance hematopoietic regeneration.
Article Details
Authors (19)
Shun Uemura
The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Masayuki Yamashita
Takako Yokomizo-Nakano
1Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Ayako Aihara
Nissan Chemical Corp., Shiraoka, Japan
Takumi Iwawaki
Nissan Chemical Industries, LTD., Shiraoka, Japan
Shuhei Koide
Yaeko Nakajima-Takagi
Motohiko Oshima
Yoshiki Omatsu
World Premier International Research Center Initiative Immunology Frontier Research Center, The University of Osaka
Yuki Matsumoto
Yoshiaki Kubota
Department of Anatomy, Keio University School of Medicine
Bahityar Rahmutulla
Atsushi Kaneda
Miki Nishio
Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine
Akira Suzuki
Division of Molecular and Cellular Biology, Kobe University Graduate School of Medicine
Takashi Nagasawa
World Premier International Research Center Initiative Immunology Frontier Research Center, The University of Osaka
Kenta Kagaya
Nissan Chemical Industries, LTD., Shiraoka, Japan
Taito Nishino
Nissan Chemical Corporation, Tokyo, Japan
Atsushi Iwama